The DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.
Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses
Open accessAbstract
The development of novel immune adjuvants is emerging as a significant area of vaccine delivery based on the continued necessity to amplify immune responses to a wide array of new antigens that are poorly immunogenic. This article specifically focuses on the application of nanoparticles and microparticles as vaccine adjuvants. Many investigators are in agreement that the size of the particles is crucial to their adjuvant activities. However, reports on correlating the size of particle-based adjuvants and the resultant immune responses have been conflicting, with investigators on both sides of the fence with impressive data in support of the effectiveness of particles with small sizes (submicron) over those with larger sizes (micron) and vice versa, while other investigators reported data that showed submicron- and micron-sized particles are effective to the same degree as immune adjuvants. We have generated a list of biological, immunological and, more importantly, vaccine formulation parameters that may have contributed to the inconsistency from different studies and made recommendations on future studies attempting to correlate the size of particulate adjuvants and the immune responses induced. The information gathered could lead to strategies to optimize the performance of nano-microparticles as immune adjuvants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biodegradable nanoparticles for drug and gene delivery to cells and tissue
Panyam, J., & Labhasetwar, V. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00228-4 · Cited by 3,361
Solid lipid nanoparticles Production, characterization and applications
Mehnert, W. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00105-3 · Cited by 3,150
Exploiting lymphatic transport and complement activation in nanoparticle vaccines
Reddy, S. T., van der Vlies, A. J., Simeoni, E., Angeli, V., Randolph, G. J., O'Neil, C. P., Lee, L. K., Swartz, M. A., & Hubbell, J. A. (2007) · Nature Biotechnology · doi:10.1038/nbt1332 · Cited by 1,350
Nanoparticles target distinct dendritic cell populations according to their size
Manolova, V., Flace, A., Bauer, M., Schwarz, K., Saudan, P., & Bachmann, M. F. (2008) · European Journal of Immunology · doi:10.1002/eji.200737984 · Cited by 1,289
Mucosal vaccines: the promise and the challenge
Neutra, M. R., & Kozlowski, P. A. (2006) · Nature Reviews Immunology · doi:10.1038/nri1777 · Cited by 1,223
Vaccine adjuvants: Current state and future trends
Petrovsky, N., & Aguilar, J. C. (2004) · Immunology & Cell Biology · doi:10.1111/j.0818-9641.2004.01272.x · Cited by 1,005
Freitas, S., Merkle, H. P., & Gander, B. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.10.015 · Cited by 923
Foged, C., Brodin, B., Frokjaer, S., & Sundblad, A. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.03.035 · Cited by 871
Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules.
Shen, Z., Reznikoff, G., Dranoff, G., & Rock, K. L. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.6.2723 · Cited by 846
In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles
Reddy, S. T., Rehor, A., Schmoekel, H. G., Hubbell, J. A., & Swartz, M. A. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.01.006 · Cited by 679
Size-Dependent Immunogenicity: Therapeutic and Protective Properties of Nano-Vaccines against Tumors
Fifis, T., Gamvrellis, A., Crimeen-Irwin, B., Pietersz, G. A., Li, J., Mottram, P. L., McKenzie, I. F. C., & Plebanski, M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.5.3148 · Cited by 664
New horizons in adjuvants for vaccine development
Reed, S. G., Bertholet, S., Coler, R. N., & Friede, M. (2009) · Trends in Immunology · doi:10.1016/j.it.2008.09.006 · Cited by 618
Pathogen recognition and development of particulate vaccines: Does size matter?
Xiang, S. D., Scholzen, A., Minigo, G., David, C., Apostolopoulos, V., Mottram, P. L., & Plebanski, M. (2006) · Methods · doi:10.1016/j.ymeth.2006.05.016 · Cited by 602
Nanotechnology in vaccine delivery
Peek, L. J., Middaugh, C. R., & Berkland, C. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.017 · Cited by 562
New horizons in adjuvants for vaccine development
Reed, S. G., Tomai, M., & Gale, M. J. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.08.008 · Cited by 554
Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome
Sharp, F. A., Ruane, D., Claass, B., Creagh, E., Harris, J., Malyala, P., Singh, M., O'Hagan, D. T., Pétrilli, V., Tschopp, J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804897106 · Cited by 540
Aguilar, J. C., & Rodríguez, E. G. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.01.111 · Cited by 494
Zinkernagel, R. M., Ehl, S., Aichele, P., Oehen, S., Kündig, T., & Hengartner, H. (1997) · Immunological Reviews · doi:10.1111/j.1600-065x.1997.tb00969.x · Cited by 489
Cationic microparticles: A potent delivery system for DNA vaccines
Singh, M., Briones, M., Ott, G., & O'Hagan, D. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.2.811 · Cited by 489
Panyam, J., & Labhasetwar, V. (2003) · Pharmaceutical Research · doi:10.1023/a:1022219003551 · Cited by 466
Recent advances in the discovery and delivery of vaccine adjuvants
O'Hagan, D. T., & Valiante, N. M. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1176 · Cited by 434
Stealth PLA-PEG nanoparticles as protein carriers for nasal administration
Tobío, M., Gref, R., Sánchez, A., Langer, R., & Alonso, M. J. (1998) · Pharmaceutical Research · doi:10.1023/a:1011922819926 · Cited by 402
Biodegradable Microspheres in Drug Delivery
Okada, H., & Toguchi, H. (1995) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v12.i1.10 · Cited by 397
Wu, N. Z., Da, D., Rudoll, T. L., Needham, D., Whorton, A. R., & Dewhirst, M. W. (1993) · PubMed · Cited by 364
Doe, B., Selby, M., Barnett, S., Baenziger, J., & Walker, C. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8578 · Cited by 340
Vaccine adjuvant systems: Enhancing the efficacy of sub-unit protein antigens
Perrie, Y., Mohammed, A. R., Kirby, D. J., McNeil, S. E., & Bramwell, V. W. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.04.036 · Cited by 333
Immunological concepts of vaccine adjuvant activity
Schijns, V. E. (2000) · Current Opinion in Immunology · doi:10.1016/s0952-7915(00)00120-5 · Cited by 330
Mottram, P. L., Leong, D., Crimeen-Irwin, B., Gloster, S., Xiang, S. D., Meanger, J., Ghildyal, R., Vardaxis, N., & Plebanski, M. (2007) · Molecular Pharmaceutics · doi:10.1021/mp060096p · Cited by 296
Gutierro, I., Hernández, R. M., Igartua, M., Gascón, A. R., & Pedraz, J. L. (2002) · Vaccine · doi:10.1016/s0264-410x(02)00435-8 · Cited by 292
Kanchan, V., & Panda, A. K. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2007.08.015 · Cited by 283
Cruz, L. J., Tacken, P. J., Fokkink, R., Joosten, B., Stuart, M. C., Albericio, F., Torensma, R., & Figdor, C. G. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.02.013 · Cited by 281
Preparation and characterization of sterile and freeze-dried sub-200 nm nanoparticles
Konan, Y. N., Gurny, R., & Allémann, E. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(01)00944-9 · Cited by 279
Elamanchili, P., Diwan, M., Cao, M., & Samuel, J. (2004) · Vaccine · doi:10.1016/j.vaccine.2003.12.032 · Cited by 246
Preparation of coated nanoparticles for a new mucosal vaccine delivery system
Borges, O., Borchard, G., Verhoef, J. C., de Sousa, A., & Junginger, H. E. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.04.037 · Cited by 240
Walter, E., Dreher, D., Kok, M., Thiele, L., Kiama, S. G., Gehr, P., & Merkle, H. P. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00413-8 · Cited by 230
Opportunities and challenges of developing thermostable vaccines
Chen, D., & Kristensen, D. (2009) · Expert Review of Vaccines · doi:10.1586/erv.09.20 · Cited by 227
Microparticles as vaccine adjuvants and delivery systems
O’Hagan, D. T., & Singh, M. (2003) · Expert Review of Vaccines · doi:10.1586/14760584.2.2.269 · Cited by 214
Stabilization of Substances in Circulation
Monfardini, C., & Veronese, F. M. (1998) · Bioconjugate Chemistry · doi:10.1021/bc970184f · Cited by 213
Nanoparticles and microparticles for drug and vaccine delivery.
Kreuter, J. (1996) · Europe PMC (PubMed Central) · Cited by 204
Uptake of poly(D,L‐lactic‐co‐glycolic acid) microspheres by antigen‐presenting cells in vivo
Newman, K. D., Elamanchili, P., Kwon, G. S., & Samuel, J. (2002) · Journal of Biomedical Materials Research · doi:10.1002/jbm.10019 · Cited by 195
Polymeric particles in vaccine delivery
Rice-Ficht, A. C., Arenas-Gamboa, A. M., Kahl-McDonagh, M. M., & Ficht, T. A. (2010) · Current Opinion in Microbiology · doi:10.1016/j.mib.2009.12.001 · Cited by 190
Thomasin, C., Corradin, G., Men, Y., Merkle, H. P., & Gander, B. (1996) · Journal of Controlled Release · doi:10.1016/0168-3659(96)01363-6 · Cited by 188
Liposomal delivery of antigen to human dendritic cells
Copland, M. J., Baird, M. A., Rades, T., McKenzie, J. L., Becker, B., Reck, F., Tyler, P. C., & Davies, N. M. (2003) · Vaccine · doi:10.1016/s0264-410x(02)00536-4 · Cited by 184
TABATA, Y. (1996) · Vaccine · doi:10.1016/s0264-410x(96)00149-1 · Cited by 181
O'Hagan, D., Singh, M., Ugozzoli, M., Wild, C., Barnett, S., Chen, M., Schaefer, M., Doe, B., Otten, G. R., & Ulmer, J. B. (2001) · Journal of Virology · doi:10.1128/jvi.75.19.9037-9043.2001 · Cited by 178
Jung, T., Kamm, W., Breitenbach, A., Hungerer, K.-D., Hundt, E., & Kissel, T. (2001) · Pharmaceutical Research · doi:10.1023/a:1011063232257 · Cited by 177
Horisawa, E., Kubota, K., Tuboi, I., Sato, K., Yamamoto, H., Takeuchi, H., & Kawashima, Y. (2002) · Pharmaceutical Research · doi:10.1023/a:1014260513728 · Cited by 169
Audran, R., Peter, K., Dannull, J., Men, Y., Scandella, E., Groettrup, M., Gander, B., & Corradin, G. (2003) · Vaccine · doi:10.1016/s0264-410x(02)00521-2 · Cited by 168
Mann, J. F. S., Shakir, E., Carter, K. C., Mullen, A. B., Alexander, J., & Ferro, V. A. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.03.040 · Cited by 166
The effects of lyophilization on the stability of liposomes containing 5-FU
Glavas-Dodov, M., Fredro-Kumbaradzi, E., Goracinova, K., Simonoska, M., Calis, S., Trajkovic-Jolevska, S., & Hincal, A. A. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.07.045 · Cited by 162
Pharmaceutical Aspects of Intranasal Delivery of Vaccines Using Particulate Systems
Sharma, S., Mukkur, T. K. S., Benson, H. A. E., & Chen, Y. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21493 · Cited by 160
Surface modifications of nanocarriers for effective intracellular delivery of anti-HIV drugs
Gunaseelan, S., Gunaseelan, K., Deshmukh, M., Zhang, X., & Sinko, P. J. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.021 · Cited by 158
Quintanar‐Guerrero, D., Ganem-Quintanar, A., Allémann, É., Fessi, H., & Doelker, É. (1998) · Journal of Microencapsulation · doi:10.3109/02652049809006840 · Cited by 157
Konan, Y. (2003) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(02)00128-5 · Cited by 152
Look, M., Bandyopadhyay, A., Blum, J. S., & Fahmy, T. M. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.011 · Cited by 152
Conjugation of ovalbumin to trimethyl chitosan improves immunogenicity of the antigen
Slütter, B., Soema, P. C., Ding, Z., Verheul, R. J., Hennink, W. E., & Jiskoot, W. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.01.007 · Cited by 146
Microparticles and polymers for the mucosal delivery of vaccines
O’Hagan, D. T. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00045-3 · Cited by 143
Zwiorek, K., Bourquin, C., Battiany, J., Winter, G., Endres, S., Hartmann, G., & Coester, C. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9410-5 · Cited by 141
Nagamoto, T., Hattori, Y., Takayama, K., & Maitani, Y. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000022414.17183.58 · Cited by 136
Vesicle Size Influences the Trafficking, Processing, and Presentation of Antigens in Lipid Vesicles
Brewer, J. M., Pollock, K. G. J., Tetley, L., & Russell, D. G. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.10.6143 · Cited by 135
Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity
Nixon, D. F., Hioe, C. E., Chen, P., Bian, Z., Kuebler, P., Li, M.-L., Qiu, H., Li, X.-M., Singh, M., Richardson, J. L., et al. (1996) · Vaccine · doi:10.1016/s0264-410x(96)00099-0 · Cited by 133
Kazzaz, J., Neidleman, J. A., Singh, M., Ott, G. S., & O’Hagan, D. T. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(00)00226-1 · Cited by 127
Katare, Y. K., Muthukumaran, T., & Panda, A. K. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.05.028 · Cited by 125
Influence of Irradiation Sterilization on Polymers Used as Drug Carriers—A Review
Sintzel, M. B., Merkli, A., Tabatabay, C., & Gurny, R. (1997) · Drug Development and Industrial Pharmacy · doi:10.3109/03639049709148693 · Cited by 116
PEG-PLA Nanoparticles as Carriers for Nasal Vaccine Delivery
Vila, A., Sánchez, A., Évora, C., Soriano, I., Jato, J. L. V., & Alonso, M. J. (2004) · Journal of Aerosol Medicine · doi:10.1089/0894268041457183 · Cited by 115
Topical immunization using nanoengineered genetic vaccines
Cui, Z., & Mumper, R. J. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00051-2 · Cited by 114
Self-citationBozdag, S., Dillen, K., Vandervoort, J., & Ludwig, A. (2005) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357056145 · Cited by 107
Methods for nano-particle based vaccine formulation and evaluation of their immunogenicity
Kalkanidis, M., Pietersz, G. A., Xiang, S. D., Mottram, P. L., Crimeen‐Irwin, B., Ardipradja, K., & Plebanski, M. (2006) · Methods · doi:10.1016/j.ymeth.2006.05.018 · Cited by 105
Igartúa, M., Hernández, R. M., Esquisabel, A., Rodríguez‐Gascón, A., Calvo, M. B., & Pedraz, J. L. (1998) · Journal of Controlled Release · doi:10.1016/s0168-3659(98)00077-7 · Cited by 105
Manocha, M., Pal, P. C., Chitralekha, K. T., Thomas, B. E., Tripathi, V., Gupta, S. D., Paranjape, R., Kulkarni, S., & Rao, D. N. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.06.031 · Cited by 103
Sayın, B., Somavarapu, S., Li, X. W., Sesardic, D., Şenel, S., & Alpar, O. H. (2009) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2009.08.010 · Cited by 102
Virus-sized vaccine delivery systems
Scheerlinck, J. Y., & Greenwood, D. L. V. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.06.016 · Cited by 99
Lyophilisation and sterilisation of liposomal vaccines to produce stable and sterile products
Mohammed, A. R., Bramwell, V. W., Coombes, A. G. A., & Perrie, Y. (2006) · Methods · doi:10.1016/j.ymeth.2006.05.025 · Cited by 95
Mallapragada, S. K., & Narasimhan, B. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.06.030 · Cited by 94
Gloria, K., & Nie, S. (2005) · Materials Today · doi:10.1016/s1369-7021(05)71034-8 · Cited by 92
A Practical Approach to the use of Nanoparticles for Vaccine Delivery
Wendorf, J. R., Singh, M., Chesko, J., Kazzaz, J., Soewanan, E., Ugozzoli, M., & O’Hagan, D. T. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20728 · Cited by 91
Physicochemical and Morphological Characterization of Polyisobutyl Cyanoacrylate Nanocapsules
Rollot, J. M., Couvreur, P., Roblot-Treupel, L., et al. (1986) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600750408 · Cited by 88
Sloat, B. R., Sandoval, M. A., Hau, A. M., et al. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.08.023 · Cited by 81
Thomas, C., Gupta, V., & Ahsan, F. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.06.006 · Cited by 79
Rieger, J., Freichels, H., Imberty, A., Putaux, J., Delair, T., Jérôme, C., & Auzély‐Velty, R. (2009) · Biomacromolecules · doi:10.1021/bm801492c · Cited by 79
Biomaterials as vaccine adjuvants
Jones, K. S. (2008) · Biotechnology Progress · doi:10.1002/btpr.10 · Cited by 77
A comparison of anionic nanoparticles and microparticles as vaccine delivery systems
Wendorf, J. R., Chesko, J., Kazzaz, J., Ugozzoli, M., Vajdy, M., O’Hagan, D. T., & Singh, M. (2008) · Human Vaccines · doi:10.4161/hv.4.1.4886 · Cited by 75
Sterile, injectable cyclodextrin nanoparticles: Effects of gamma irradiation and autoclaving
Memiṣoǧlu, E., & Hıncal, A. A. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.12.013 · Cited by 73
Briones, M., Singh, M., Ugozzoli, M., Kazzaz, J., Klakamp, S. L., Ott, G. S., & O’Hagan, D. T. (2001) · Pharmaceutical Research · doi:10.1023/a:1011053931523 · Cited by 73
Jain, S., Yap, W. T., & Irvine, D. J. (2005) · Biomacromolecules · doi:10.1021/bm0503221 · Cited by 72
Particulate delivery systems for vaccines: what can we expect?
Bramwell, V. W., & Perrie, Y. (2006) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.58.6.0002 · Cited by 65
Influence of sterilization processes on poly(ε-caprolactone) nanospheres
Masson, V., Maurin, F., Fessi, H., & Devissaguet, J. P. (1997) · Biomaterials · doi:10.1016/s0142-9612(96)00144-5 · Cited by 65
Towards clinical testing of a single-administration tetanus vaccine based on PLA/PLGA microspheres
Johansen, P. (2000) · Vaccine · doi:10.1016/s0264-410x(00)00343-1 · Cited by 63
Experience with hepatitis A and B vaccines
Davis, J. P. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.07.011 · Cited by 49
Coppi, G., Iannuccelli, V., Sala, N., & Bondi, M. (2004) · Journal of Microencapsulation · doi:10.1080/02652040400015437 · Cited by 45
Ambiguities in the preclinical quality assessment of microparticulate vaccines
Johansen, P. (2000) · Trends in biotechnology · doi:10.1016/s0167-7799(00)01437-2 · Cited by 43
A novel nanoparticulate adjuvant for immunotherapy with Lolium perenne
Gómez, S., Gamazo, C., Román, B. S., Grau, A., Espuelas, S., Ferrer, M., Sanz, M. L., & Irache, J. M. (2009) · Journal of Immunological Methods · doi:10.1016/j.jim.2009.06.005 · Cited by 39
Size effect on the antibody production induced by biodegradable microspheres containing antigen
Nakaoka, R., Inoue, Y., Tabata, Y., et al. (1996) · Vaccine · doi:10.1016/s0264-410x(96)00016-3 · Cited by 38
Schmidt, C. S., Morrow, W. J., & Sheikh, N. A. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.3.391 · Cited by 35
Enhanced immune response induced by BSA loaded in hydroxyethylstarch microparticles
Balasse, E., Odot, J., Gatouillat, G., Andry, M. C., & Madoulet, C. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.11.021 · Cited by 28
A novel vaccine adjuvant for recombinant flu antigens
Chang, S., Warner, J. F., Liang, L. R., et al. (2009) · Biologicals · doi:10.1016/j.biologicals.2009.02.019 · Cited by 26
Cited by
Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems
Karimi, M., Ghasemi, A., Sahandi Zangabad, P., Rahighi, R., Moosavi Basri, S. M., Mirshekari, H., Amiri, M., Shafaei Pishabad, Z., Aslani, A., Bozorgomid, M., et al. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00798d · Cited by 1,519
Key roles of adjuvants in modern vaccines
Reed, S. G., Orr, M. T., & Fox, C. B. (2013) · Nature Medicine · doi:10.1038/nm.3409 · Cited by 1,419
Zhao, L., Seth, A., Wibowo, N., Zhao, C.-X., Mitter, N., Yu, C., & Middelberg, A. P. J. (2014) · Vaccine · doi:10.1016/j.vaccine.2013.11.069 · Cited by 919
Synthetic Nanoparticles for Vaccines and Immunotherapy
Irvine, D. J., Hanson, M. C., Rakhra, K., & Tokatlian, T. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00109 · Cited by 763
Osteoimmunomodulation for the development of advanced bone biomaterials
Chen, Z., Klein, T., Murray, R. Z., Crawford, R., Chang, J., Wu, C., & Xiao, Y. (2016) · Materials Today · doi:10.1016/j.mattod.2015.11.004 · Cited by 730
Metadata
- Authors
- Oyewumi, M. O., Kumar, A., & Cui, Z.
- Venue
- Expert Review of Vaccines
- Publisher
- Informa UK Limited
- Published
- 2010-09
- Volume
- 9
- Issue
- 9
- Pages
- 1095-1107
- ISSN
- 1476-0584 (ISSN-L)
- 1744-8395
- OpenAlex
- W2106183630
- Cited by
- 547
- References
- 97
- FWCI
- 8.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.